⌕
Palvella Therapeutics · PVLA · Nasdaq
Tenet 34 · Weak
Compare
$144.60−5.17%At closeTenet 34 · Weak
$144.60−7.88 (−5.17%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Palvella Therapeutics (PVLA) Key Ratios

Valuation, quality, health and growth. Every ratio ranked against its sector peers — the number we score — with its own ten-year record shown beside it for context.

Sources Company filings and market prices Filings and pricesRatios computed How we compute thisNot investment advice
4
VALUE
High multiples vs sector
premium price vs peers
29
QUALITY
Weak
below-peer returns
68
HEALTH
Sturdy
conservative balance sheet
—
GROWTH
No data
no inputs scored

A weak business at high multiples for its sector: value 4, quality 29, health 68, each a percentile within Healthcare.

Every figure here is from the latest fiscal year. The note under each row says why.track = where peers land, worse → better (direction-adjusted: right always means better)▏sector median● you are here▲ where today's value sits in the company's own 10-year record (context, not scored)hover any metric for its formula
4th pctilepremium price vs peers
Earnings yield (EBIT/EV)EBIT (operating income) for the latest fiscal year ÷ enterprise value on the current market cap (Greenblatt). The vendor's own earnings yield is net income to common ÷ market cap, a different figure.—Not reported in the company's filings for this period.
P/E—Not reported in the company's filings for this period.
P/B62.14th pctileown record too shortMarket cap at the close of Nov 13, 2026 ÷ book equity, fiscal 2025 (Dec 31, 2025)Fiscal 2025: files no quarterly statements
P/FCF—Not reported in the company's filings for this period.
EV / EBITDA—Not reported in the company's filings for this period.
68th pctileconservative balance sheet
Current ratio5.2066th pctileFiscal 2025 (Dec 31, 2025)Fiscal 2025: files no quarterly statements
Quick ratio(Cash, short-term investments and receivables) ÷ current liabilities, as the data vendor builds it. Its receivables include non-trade receivables, which Tenet's balance sheet shows inside other current assets.5.2068th pctileFiscal 2025 (Dec 31, 2025)Fiscal 2025: files no quarterly statements
Net debt / EBITDA(Total debt − cash) ÷ EBITDA—Not meaningful: EBITDA is zero or negative.
Interest coverage—Not meaningful: operating income is zero or negative.
Debt / equity0.0271st pctileown record too shortFiscal 2025 (Dec 31, 2025)Fiscal 2025: files no quarterly statements
29th pctilebelow-peer returns
ROIC−80%10th pctileFiscal 2025 (Dec 31, 2025)Fiscal 2025: files no quarterly statements
ROE−149%5th pctileown record too shortFiscal 2025 (Dec 31, 2025)Fiscal 2025: files no quarterly statements
Gross margin0.0%3rd pctileFiscal 2025 (Dec 31, 2025)Fiscal 2025: files no quarterly statements
Net margin0.0%41st pctileFiscal 2025 (Dec 31, 2025)Fiscal 2025: files no quarterly statements
Income quality (CFO/NI)—Not meaningful: the company made a loss.
Piotroski F2 / 916th pctileown record too shortFiscal 2025 (Dec 31, 2025)
Altman Z32.996th pctileown record too shortFiscal 2025 (Dec 31, 2025)Fiscal 2025: files no quarterly statements
no inputs scored
Revenue CAGRThe yearly rate that compounds the earliest fiscal year's revenue into the latest one, over the true number of fiscal years between them (up to five). When the earliest year's revenue is zero or negative, the rate starts from the first later year with at least $10M of revenue, provided at least three years remain.—This growth figure starts in a period outside the history your plan includes.
EPS CAGR—This growth figure starts in a period outside the history your plan includes.
FCF margin—Not reported in the company's filings for this period.
the receipts behind the numbers above
Greenblatt earnings yield—EBIT ÷ EV The vendor's "earningsYield" is NI ÷ market cap, which is not Greenblatt's formula.
ROIC−80%NOPAT ÷ invested capital The vendor's simple ROIC, not its tiny-base roic tag; withheld when a negative EBIT flips its sign.
Interest coverage— Guarded, not faked: we have no interest-expense figure on file for this company, so it's excluded from the ranking instead of rendered as garbage.
Percentiles computed nightly against 409 Healthcare peers from our ingested fundamentals DB · raw statements for corrected metrics. Direction-adjusted: for "lower is better" ratios (P/E, D/E…) the percentile is flipped so right always means better. The percentile is the stock's rank among sector peers, the number that is scored. The triangle marks where the current value sits in the company's own ten-year annual record, shown for context and never blended into the score. Computed Nov 16, 2026 · Not investment advice.

What is Palvella Therapeutics' Piotroski F-Score?

Palvella Therapeutics' Piotroski F-Score is 2 of 9 for fiscal 2025.

What is Palvella Therapeutics' Altman Z-Score?

Palvella Therapeutics' Altman Z-Score is 32.9, fiscal 2025 (Dec 31, 2025).

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.